Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm neoadjuvant adebrelimab + apatinib + chemotherapy in resectable stage II-IIIB NSCLC
ChiCTR2400084169Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- May 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab and Rivoceranib in non-small cell lung cancer (NSCLC), sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Pathological complete response. Planned start May 2024; status: not yet recruiting.
02
Drugs
adebrelimabRivoceranib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2400084169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400084169.